Monica Kraft is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
700 Childrens Dr
Columbus, OH 432052664
Telephone
614-722-4411Provider last certified this registry record 13 Dec 2024.
Clinical trials
- Quantifying the Burden of Type 2 (T2) Inflammation in Asthma
Sponsor: Icahn School of Medicine at Mount Sinai
- AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)
Sponsor: Chiesi Farmaceutici S.p.A.
- Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Sponsor: Milton S. Hershey Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20256 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
75.3%Histamine-1 Receptor Antagonist24.5%Azelastine Hcl100%Part D≥31 patientsCorticosteroid18.4%Fluticasone Propionate100%Part D≥24 patients+ 4 more classes in this area
Blood & clotting
10.4%Human C1 Esterase Inhibitor7.1%Haegarda100%Part D<11 patientsBradykinin B2 Receptor Antagonist3.3%Icatibant100%Part D<11 patientsDermatology
6.9%Interleukin-4 Receptor alpha Antagonist6.9%Dupixent Pen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”